<?xml version="1.0" encoding="utf-8"?> <rss version="2.0"> <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/"> <title>Marina Biotech, Inc.</title> <link>https://www.globenewswire.com/rssfeed/organization/Bmf35y6S0fTU3xG5YbyP4Q==</link> <description>Contains the last 20 releases</description> <copyright>Copyright 2017, Marina Biotech, Inc.</copyright> <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor> <lastBuildDate>Wed, 05 Jul 2017 12:30:00 GMT</lastBuildDate> <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/07/05/1049294/0/en/Marina-Biotech-Announces-the-Appointment-of-Dr-Vuong-Trieu-as-Executive-Chairman.html</guid> <link>https://www.globenewswire.com/news-release/2017/07/05/1049294/0/en/Marina-Biotech-Announces-the-Appointment-of-Dr-Vuong-Trieu-as-Executive-Chairman.html</link> <title>Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman </title> <description><![CDATA[<p><em><p>Company Also Announces Closing of a Note Financing Led by Dr. Trieu and Dr. Hwang, CSO</p></em></p><p>CITY OF INDUSTRY, CA--(Marketwired - Jul 5, 2017) - <strong> </strong>Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that Dr. Vuong Trieu, has been appointed to serve as Executive Chairman after having served as Chairman of the Board since November of 2016. As Executive Chairman, Dr. Trieu will take on a more active role in the day-to-day operations of the business and future developments of the Company.</p>]]></description> <pubDate>Wed, 05 Jul 2017 12:30 GMT</pubDate> <dc:identifier>1049294</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/26/1049292/0/en/Marina-Biotech-Appoints-Chief-Commercial-Officer-to-Lead-Sales-and-Marketing-of-Prestalia-R.html</guid> <link>https://www.globenewswire.com/news-release/2017/06/26/1049292/0/en/Marina-Biotech-Appoints-Chief-Commercial-Officer-to-Lead-Sales-and-Marketing-of-Prestalia-R.html</link> <title>Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R) </title> <description><![CDATA[<p><em><p>Company to narrow its business focus to pain and hypertension; Company plans to sell or divest the oligonucleotide therapeutic assets</p></em></p><p>CITY OF INDUSTRY, CA--(Marketwired - Jun 26, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Erik Emerson will join the company in the newly created role of Chief Commercial Officer, effective immediately. </p>]]></description> <pubDate>Mon, 26 Jun 2017 12:30 GMT</pubDate> <dc:identifier>1049292</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/06/1049290/0/en/Marina-Biotech-Acquires-Prestalia-R-a-U-S-FDA-Approved-Drug-for-Patients-Whose-Blood-Pressure-Is-Not-Adequately-Controlled-by-Monotherapy.html</guid> <link>https://www.globenewswire.com/news-release/2017/06/06/1049290/0/en/Marina-Biotech-Acquires-Prestalia-R-a-U-S-FDA-Approved-Drug-for-Patients-Whose-Blood-Pressure-Is-Not-Adequately-Controlled-by-Monotherapy.html</link> <title>Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy </title> <description><![CDATA[<p><em><p>Prestalia provides an immediate commercial opportunity for Marina</p> <p>Product will be marketed using the patented telehealth technology platform, DyrctAxess(TM)</p></em></p><p>CITY OF INDUSTRY, CA--(Marketwired - Jun 6, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that it has acquired Prestalia®, a treatment of hypertension, from Symplmed Pharmaceuticals Inc. Hypertension remains a significant health issue in the U.S., affecting approximately 34% of adults ages 20 and over, in 2013 to 2014; and approximately 30,200 deaths from essential hypertension and hypertensive renal disease, in 2014, according to the CDC.</p>]]></description> <pubDate>Tue, 06 Jun 2017 12:30 GMT</pubDate> <dc:identifier>1049290</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/30/1049288/0/en/Marina-Biotech-to-Introduce-Its-Therapeutic-Microbiome-Programs-Against-Gastrointestinal-Diseases.html</guid> <link>https://www.globenewswire.com/news-release/2017/05/30/1049288/0/en/Marina-Biotech-to-Introduce-Its-Therapeutic-Microbiome-Programs-Against-Gastrointestinal-Diseases.html</link> <title>Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - May 30, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it will be presenting two poster presentations at the 22nd Annual Meeting of the RNA Society being held from May 30 to June 3, 2017, in Prague, Czech Republic, at the Prague Congress Center.</p>]]></description> <pubDate>Tue, 30 May 2017 12:45 GMT</pubDate> <dc:identifier>1049288</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/27/1049286/0/en/Marina-Biotech-to-Participate-in-Joseph-Gunnar-s-Pioneers-2017-Conference-on-May-2.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/27/1049286/0/en/Marina-Biotech-to-Participate-in-Joseph-Gunnar-s-Pioneers-2017-Conference-on-May-2.html</link> <title>Marina Biotech to Participate in Joseph Gunnar's Pioneers 2017 Conference on May 2 </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Apr 27, 2017) - <strong> </strong>Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that Joseph Ramelli, Chief Executive Officer, will present at Joseph Gunnar's Pioneers 2017 Conference to be held at the Mandarin Oriental Hotel in New York City on Tuesday, May 2, 2017 at 2:30 pm ET.</p>]]></description> <pubDate>Thu, 27 Apr 2017 18:00 GMT</pubDate> <dc:identifier>1049286</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/05/1049284/0/en/Marina-Biotech-Provides-Business-Update.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/05/1049284/0/en/Marina-Biotech-Provides-Business-Update.html</link> <title>Marina Biotech Provides Business Update </title> <description><![CDATA[<p><em><p>10-K for year ended December 31, 2016 Filed with the SEC</p></em></p><p>CITY OF INDUSTRY, CA--(Marketwired - Apr 5, 2017) - <strong> </strong> Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, provided today a corporate update to investors, following the filing of its 10-K for the year ended December 31, 2016 with the SEC.</p>]]></description> <pubDate>Wed, 05 Apr 2017 12:45 GMT</pubDate> <dc:identifier>1049284</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/03/1049282/0/en/Marina-Biotech-Signs-Definitive-Agreement-with-Windlas-Healthcare-to-Manufacture-IT-102-FDC-Bi-Layer-Tablet.html</guid> <link>https://www.globenewswire.com/news-release/2017/04/03/1049282/0/en/Marina-Biotech-Signs-Definitive-Agreement-with-Windlas-Healthcare-to-Manufacture-IT-102-FDC-Bi-Layer-Tablet.html</link> <title>Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Apr 3, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it has signed a definitive agreement with Windlas Healthcare Limited for the manufacture of its IT-102 fixed-dose combination (FDC) bi-layer tablets.</p>]]></description> <pubDate>Mon, 03 Apr 2017 13:00 GMT</pubDate> <dc:identifier>1049282</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/29/1049280/0/en/Marina-Biotech-to-Present-Data-on-IT-102-and-IT-103-at-2017-American-Association-for-Cancer-Research-Annual-Meeting.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/29/1049280/0/en/Marina-Biotech-to-Present-Data-on-IT-102-and-IT-103-at-2017-American-Association-for-Cancer-Research-Annual-Meeting.html</link> <title>Marina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research Annual Meeting </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Mar 29, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that three new posters on the use of IT-102 and IT-103 for the treatment of cancer have been selected to be presented at the American Association for Cancer Research Annual Meeting being held on April 1-5, 2017 in Washington, DC.</p>]]></description> <pubDate>Wed, 29 Mar 2017 13:05 GMT</pubDate> <dc:identifier>1049280</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/24/1049278/0/en/Marina-Biotech-to-Present-Data-on-Vascular-Resistance-and-Cancer-at-the-Endocrine-Society-Annual-Meeting-on-April-1.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/24/1049278/0/en/Marina-Biotech-to-Present-Data-on-Vascular-Resistance-and-Cancer-at-the-Endocrine-Society-Annual-Meeting-on-April-1.html</link> <title>Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1 </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Mar 24, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster<sup>1</sup> on the use of antihypertensive for the treatment of cancer by targeting vascular resistance in the tumor will be presented at the Endocrine Society Annual Meeting to be held on April 1-4, 2017, at Orange County Convention Center, Orlando, FL. </p>]]></description> <pubDate>Fri, 24 Mar 2017 13:10 GMT</pubDate> <dc:identifier>1049278</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/13/1049276/0/en/Marina-Biotech-to-Present-A-Late-Breaking-Poster-on-the-Safety-and-Tolerability-of-CEQ508-for-FAP-at-the-Society-of-Toxicology-56th-Annual-Meeting-on-March-16.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/13/1049276/0/en/Marina-Biotech-to-Present-A-Late-Breaking-Poster-on-the-Safety-and-Tolerability-of-CEQ508-for-FAP-at-the-Society-of-Toxicology-56th-Annual-Meeting-on-March-16.html</link> <title>Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16 </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Mar 13, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster<sup>1</sup> on the safety and tolerability findings of the Company's CEQ508, RNAi therapeutic in Familial Adenomatous Polyposis (FAP) will be presented at the Society of Toxicology 56<sup>th</sup> Annual Meeting to be held at the Baltimore Convention Center in Baltimore, MD on March 12-16, 2017. </p>]]></description> <pubDate>Mon, 13 Mar 2017 13:05 GMT</pubDate> <dc:identifier>1049276</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/02/1049274/0/en/Marina-Biotech-to-Present-New-Data-for-IT-102-and-IT-103-at-the-7th-International-Conference-on-Fixed-Combination-in-Cannes-France.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/02/1049274/0/en/Marina-Biotech-to-Present-New-Data-for-IT-102-and-IT-103-at-the-7th-International-Conference-on-Fixed-Combination-in-Cannes-France.html</link> <title>Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Mar 2, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that new data related to its IT-102 and IT-103 will be presented at the 7<sup>th</sup> International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus in Cannes, France on March 2-5, 2017.</p>]]></description> <pubDate>Thu, 02 Mar 2017 13:50 GMT</pubDate> <dc:identifier>1049274</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/01/1049273/0/en/Marina-Biotech-to-Participate-in-the-29th-Annual-ROTH-Conference.html</guid> <link>https://www.globenewswire.com/news-release/2017/03/01/1049273/0/en/Marina-Biotech-to-Participate-in-the-29th-Annual-ROTH-Conference.html</link> <title>Marina Biotech to Participate in the 29th Annual ROTH Conference </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Mar 1, 2017) - <strong> </strong>Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, has been invited to present at the 29th Annual ROTH Conference to be held at The Ritz-Carlton, Laguna Niguel in Dana Point, CA. </p>]]></description> <pubDate>Wed, 01 Mar 2017 20:15 GMT</pubDate> <dc:identifier>1049273</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/21/1049271/0/en/Marina-Biotech-Appoints-Dr-Seymour-Fein-as-Chief-Medical-Officer.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/21/1049271/0/en/Marina-Biotech-Appoints-Dr-Seymour-Fein-as-Chief-Medical-Officer.html</link> <title>Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Feb 21, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Seymour Fein, M.D., as Chief Medical Officer</p>]]></description> <pubDate>Tue, 21 Feb 2017 14:05 GMT</pubDate> <dc:identifier>1049271</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/14/1049269/0/en/Marina-Biotech-Announces-Key-Additions-to-its-Executive-Management-Team.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/14/1049269/0/en/Marina-Biotech-Announces-Key-Additions-to-its-Executive-Management-Team.html</link> <title>Marina Biotech Announces Key Additions to its Executive Management Team </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Feb 14, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Larn Hwang, Ph.D. as Chief Scientific Officer and Mihir Munsif as Chief Operating Officer.</p>]]></description> <pubDate>Tue, 14 Feb 2017 14:20 GMT</pubDate> <dc:identifier>1049269</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/10/1049267/0/en/Marina-Biotech-Completes-Share-Issuance-at-a-Valuation-of-0-29-Per-Share.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/10/1049267/0/en/Marina-Biotech-Completes-Share-Issuance-at-a-Valuation-of-0-29-Per-Share.html</link> <title>Marina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Feb 10, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it has entered into two privately negotiated transactions pursuant to which it will issue an aggregate of approximately 6.15 million shares of its common stock for an effective price per share of $0.29. As a result of such transactions, the company will reduce the aggregate amount of its outstanding payables to its service providers by approximately $1.78 million.</p>]]></description> <pubDate>Fri, 10 Feb 2017 14:27 GMT</pubDate> <dc:identifier>1049267</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/07/1049265/0/en/Marina-Biotech-Announces-a-License-Agreement-to-SMARTICLES.html</guid> <link>https://www.globenewswire.com/news-release/2017/02/07/1049265/0/en/Marina-Biotech-Announces-a-License-Agreement-to-SMARTICLES.html</link> <title>Marina Biotech Announces a License Agreement to SMARTICLES </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Feb 7, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that they have entered into a license agreement regarding the Company's SMARTICLES platform for the delivery of nanoparticles including small molecules, peptides, proteins and biologics. This represents the first time that the Company's SMARTICLES technologies have been licensed in connection with nanoparticles delivering small molecules, peptides, proteins and biologics. Under terms of the agreement, Marina could receive up to $90MM in success based milestones. Further details of the agreement were not disclosed.</p>]]></description> <pubDate>Tue, 07 Feb 2017 15:14 GMT</pubDate> <dc:identifier>1049265</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2017/01/03/1049263/0/en/Marina-Biotech-Granted-European-Claims-Covering-Bacteria-Mediated-Gene-Silencing.html</guid> <link>https://www.globenewswire.com/news-release/2017/01/03/1049263/0/en/Marina-Biotech-Granted-European-Claims-Covering-Bacteria-Mediated-Gene-Silencing.html</link> <title>Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Jan 3, 2017) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that the European Patent Office intends to grant the company a patent for Bacteria Mediated Gene Silencing (EP 08768475.9, European Patent 2173875).</p>]]></description> <pubDate>Tue, 03 Jan 2017 13:50 GMT</pubDate> <dc:identifier>1049263</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/12/27/1049261/0/en/Marina-Biotech-to-Update-Its-tkRNAi-Clinical-Program-at-Biotech-Showcase.html</guid> <link>https://www.globenewswire.com/news-release/2016/12/27/1049261/0/en/Marina-Biotech-to-Update-Its-tkRNAi-Clinical-Program-at-Biotech-Showcase.html</link> <title>Marina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Dec 27, 2016) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that the company's Chief Executive Officer, Joseph W. Ramelli, and its Chairman, Dr. Vuong Trieu, will present a corporate update of the recent merger with IthenaPharma and clinical updates of the company's tkRNAi program at the 9<sup>th</sup> Annual Biotech Showcase on January 9, 2017 at 8:30 am PT. The Biotech Showcase event runs from January 9-11, 2017 concurrently with the J.P. Morgan Healthcare Conference. </p>]]></description> <pubDate>Tue, 27 Dec 2016 13:40 GMT</pubDate> <dc:identifier>1049261</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/12/14/1049260/0/en/Philippe-P-Calais-to-Join-Marina-Biotech-s-Board-of-Directors.html</guid> <link>https://www.globenewswire.com/news-release/2016/12/14/1049260/0/en/Philippe-P-Calais-to-Join-Marina-Biotech-s-Board-of-Directors.html</link> <title>Philippe P. Calais to Join Marina Biotech's Board of Directors </title> <description><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Dec 14, 2016) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for cancer and rare diseases, today announced that Dr. Philippe P. Calais was elected to the Marina Biotech board of directors, which he will join effective January 1, 2017. Dr. Calais currently serves as Chief Executive Officer of Isarna Therapeutics. </p>]]></description> <pubDate>Wed, 14 Dec 2016 13:40 GMT</pubDate> <dc:identifier>1049260</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> <item> <guid isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/25/1049258/0/en/Marina-Biotech-to-Present-at-the-9th-Annual-LD-Micro-Main-Event.html</guid> <link>https://www.globenewswire.com/news-release/2016/11/25/1049258/0/en/Marina-Biotech-to-Present-at-the-9th-Annual-LD-Micro-Main-Event.html</link> <title>Marina Biotech to Present at the 9th Annual LD Micro Main Event </title> <description><![CDATA[<p>BOTHELL, WA--(Marketwired - Nov 25, 2016) - Marina Biotech, Inc. (<exchange name="OTCQB">OTCQB</exchange>: <ticker name="MRNA">MRNA</ticker>) today announced that its CEO, Joseph W. Ramelli, will be presenting at the LD Micro Main Event on Thursday, December 8, 2016 at 8am PT, at the Luxe Sunsent Boulevard Hotel in Los Angeles.  Management will update investors on the synergy derived from the recent merger with IthenaPharma to deliver unparalleled targeted therapy against colorectal cancer as well as familial adenomatous polyposis (FAP). </p>]]></description> <pubDate>Fri, 25 Nov 2016 12:00 GMT</pubDate> <dc:identifier>1049258</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Marina Biotech, Inc.</dc:contributor> <dc:modified>Thu, 14 Sep 2017 02:28 GMT</dc:modified> </item> </channel> </rss>